Biomea Fusion (BMEA) Competitors $1.93 -0.05 (-2.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.92 -0.01 (-0.78%) As of 09/12/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMEA vs. ERAS, ITOS, SLDB, ATXS, NBTX, FULC, CGEM, KMDA, INBX, and AURAShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), Kamada (KMDA), Inhibrx Biosciences (INBX), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. Its Competitors Erasca iTeos Therapeutics Solid Biosciences Astria Therapeutics Nanobiotix Fulcrum Therapeutics Cullinan Therapeutics Kamada Inhibrx Biosciences Aura Biosciences Erasca (NASDAQ:ERAS) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership. Which has more risk and volatility, ERAS or BMEA? Erasca has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Does the media prefer ERAS or BMEA? In the previous week, Erasca had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Erasca and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.40 beat Erasca's score of 0.84 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ERAS or BMEA? Erasca is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.45-3.47Biomea FusionN/AN/A-$138.43M-$3.03-0.64 Do analysts prefer ERAS or BMEA? Erasca presently has a consensus price target of $3.71, indicating a potential upside of 138.10%. Biomea Fusion has a consensus price target of $14.80, indicating a potential upside of 666.84%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.17 Is ERAS or BMEA more profitable? Erasca's return on equity of -31.19% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -31.19% -26.34% Biomea Fusion N/A -243.95%-140.74% Do institutionals and insiders have more ownership in ERAS or BMEA? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 14.4% of Erasca shares are owned by insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryBiomea Fusion beats Erasca on 9 of the 14 factors compared between the two stocks. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$114.85M$3.15B$5.79B$10.19BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-0.6421.4375.4026.02Price / SalesN/A419.38514.85113.09Price / CashN/A44.4425.8129.91Price / Book1.369.6112.166.25Net Income-$138.43M-$53.29M$3.29B$270.76M7 Day Performance0.52%0.13%0.74%3.87%1 Month Performance14.20%5.55%5.00%5.49%1 Year Performance-75.41%10.44%62.55%25.86% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion3.4384 of 5 stars$1.93-2.5%$14.80+666.8%-75.4%$114.85MN/A-0.6450News CoveragePositive NewsERASErasca2.366 of 5 stars$1.55-3.7%$3.71+139.6%-47.5%$456.71MN/A-3.44120Analyst DowngradeITOSiTeos Therapeutics3.4365 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences3.1529 of 5 stars$5.13-6.7%$15.00+192.4%-32.0%$428.28M$8.09M-1.83100Positive NewsAnalyst DowngradeATXSAstria Therapeutics2.8317 of 5 stars$7.43-1.2%$29.00+290.3%-33.3%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.64 of 5 stars$8.71+0.1%$8.00-8.2%+96.0%$417.11M$39.18M0.00100News CoverageUpcoming EarningsShort Interest ↑Gap UpFULCFulcrum Therapeutics2.6202 of 5 stars$7.27-5.1%$7.57+4.1%+120.1%$414.34M$80M-5.96100News CoveragePositive NewsShort Interest ↓CGEMCullinan Therapeutics2.1928 of 5 stars$6.84-2.1%$26.80+291.8%-63.6%$412.93MN/A-2.1230News CoverageAnalyst ForecastKMDAKamada4.4822 of 5 stars$7.22+1.1%$13.00+80.1%+28.6%$410.59M$160.95M21.24360Short Interest ↓INBXInhibrx Biosciences1.0576 of 5 stars$29.10+3.3%N/A+67.7%$408.20M$200K-2.75166News CoveragePositive NewsAURAAura Biosciences2.2463 of 5 stars$6.47-0.2%$22.00+240.0%-38.6%$402.54MN/A-3.3050Positive News Related Companies and Tools Related Companies ERAS Alternatives ITOS Alternatives SLDB Alternatives ATXS Alternatives NBTX Alternatives FULC Alternatives CGEM Alternatives KMDA Alternatives INBX Alternatives AURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMEA) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMEA Stock Alerts